TrialNature communications2026

A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial.

Christian Ottensmeier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.